Larvol Delta - PureTech-Founded-Entity-Celea-Therapeutics-Completes-180-Million-Financing-to-Advance-Deupirfenidone-as-a-Potential-New-Standard-of-Care-to-Treat-Idiopathic-Pulmonary-Fibrosis-IPF

deupirfenidone (LYT-100) - Celea Therapeutics

https://www.businesswire.com/news/home/20260701663109/en/PureTech-Founded-Entity-Celea-Therapeutics-Completes-%24180-Million-Financing-to-Advance-Deupirfenidone-as-a-Potential-New-Standard-of-Care-to-Treat-Idiopathic-Pulmonary-Fibrosis-IPF

Jul 2, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next